Concord Biotech Limited, an India-based R&D-driven biopharma company specializing in fermentation-based APIs for immunosuppressants and oncology, reported a decline in financial performance for Q2FY26.
Financial Highlights:
- Revenues declined 20.32% year-on-year to ₹247 crore from ₹310 crore.
- Total expenses decreased 6.35% to ₹177 crore from ₹189 crore.
- Consolidated net profit dropped 34.38% to ₹63 crore from ₹96 crore.
- Earnings per share fell 33.55% to ₹6.08 from ₹9.15.
The profit decline was primarily due to lower revenues despite cost reductions. The company is focusing on strengthening its product pipeline and operational efficiencies.
Outlook:
Concord Biotech aims to enhance R&D, expand its product portfolio, and improve manufacturing capabilities to drive future growth. It is well-positioned to benefit from growing demand in immunosuppressants and oncology segments.
Explore the company’s past earnings and latest concall transcripts, click here to visit the AlphaStreet India News Channel.
